125 related articles for article (PubMed ID: 37925965)
21. The influence of young age on outcome in early stage breast cancer.
Fowble BL; Schultz DJ; Overmoyer B; Solin LJ; Fox K; Jardines L; Orel S; Glick JH
Int J Radiat Oncol Biol Phys; 1994 Aug; 30(1):23-33. PubMed ID: 8083119
[TBL] [Abstract][Full Text] [Related]
22. Endocrine sensitivity is decisive for patient outcome in small node-negative breast cancers (BC) (pT1a,b) - results from the Munich Cancer Registry.
Kolben T; Harbeck N; Wuerstlein R; Schubert-Fritschle G; Bauerfeind I; Schrodi S; Engel J
Breast; 2015 Feb; 24(1):24-31. PubMed ID: 25543874
[TBL] [Abstract][Full Text] [Related]
23. Validation of the PREDICT Prognostication Tool in US Patients With Breast Cancer.
Stabellini N; Cao L; Towe CW; Miller ME; Sousa-Santos AH; Amin AL; Montero AJ
J Natl Compr Canc Netw; 2023 Oct; 21(10):1011-1019.e6. PubMed ID: 37856198
[TBL] [Abstract][Full Text] [Related]
24. External validation of 87 clinical prediction models supporting clinical decisions for breast cancer patients.
Hueting TA; van Maaren MC; Hendriks MP; Koffijberg H; Siesling S
Breast; 2023 Jun; 69():382-391. PubMed ID: 37087910
[TBL] [Abstract][Full Text] [Related]
25. Is information from axillary dissection relevant to patients with clinically node-negative breast cancer?
Chua B; Ung O; Taylor R; Boyages J
Breast J; 2003; 9(6):478-84. PubMed ID: 14616942
[TBL] [Abstract][Full Text] [Related]
26. The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real-world early-stage breast cancer.
Goldstein DA; Mayer C; Shochat T; Reinhorn D; Moore A; Sarfaty M; Yerushalmi R; Goldvaser H
Cancer Med; 2020 Jul; 9(13):4603-4612. PubMed ID: 32372569
[TBL] [Abstract][Full Text] [Related]
27. [The importance of steroid receptors for the prognosis and hormone treatment of breast cancer patients: a retrospective study in Southeastern Netherlands].
Voogd AC; Crommelin MA; Repelaer van Driel OJ; Tutein Nolthenius-Puylaert MC; Vreugdenhil G; Coebergh JW
Ned Tijdschr Geneeskd; 1998 Aug; 142(31):1772-8. PubMed ID: 9856143
[TBL] [Abstract][Full Text] [Related]
28. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.
Fisher B; Jeong JH; Dignam J; Anderson S; Mamounas E; Wickerham DL; Wolmark N
J Natl Cancer Inst Monogr; 2001; (30):62-6. PubMed ID: 11773294
[TBL] [Abstract][Full Text] [Related]
29. How Does the Skeletal Oncology Research Group Algorithm's Prediction of 5-year Survival in Patients with Chondrosarcoma Perform on International Validation?
Bongers MER; Karhade AV; Setola E; Gambarotti M; Groot OQ; Erdoğan KE; Picci P; Donati DM; Schwab JH; Palmerini E
Clin Orthop Relat Res; 2020 Oct; 478(10):2300-2308. PubMed ID: 32433107
[TBL] [Abstract][Full Text] [Related]
30. Validation of the online prediction model CancerMath in the Dutch breast cancer population.
Hoveling LA; van Maaren MC; Hueting T; Strobbe LJA; Hendriks MP; Sonke GS; Siesling S
Breast Cancer Res Treat; 2019 Dec; 178(3):665-681. PubMed ID: 31471837
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of adjuvant chemotherapy according to hormone receptor status in young patients with breast cancer: a pooled analysis.
van der Hage JA; Mieog JS; van de Vijver MJ; van de Velde CJ;
Breast Cancer Res; 2007; 9(5):R70. PubMed ID: 17931406
[TBL] [Abstract][Full Text] [Related]
32. The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.
van Ramshorst MS; van der Heiden-van der Loo M; Dackus GM; Linn SC; Sonke GS
Breast Cancer Res Treat; 2016 Jul; 158(2):361-71. PubMed ID: 27357813
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
; Castiglione-Gertsch M; O'Neill A; Price KN; Goldhirsch A; Coates AS; Colleoni M; Nasi ML; Bonetti M; Gelber RD
J Natl Cancer Inst; 2003 Dec; 95(24):1833-46. PubMed ID: 14679153
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant systemic therapy for women with node-negative breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
CMAJ; 1998 Feb; 158 Suppl 3():S43-51. PubMed ID: 9484278
[TBL] [Abstract][Full Text] [Related]
35. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
Bueno-de-Mesquita JM; van Harten WH; Retel VP; van 't Veer LJ; van Dam FS; Karsenberg K; Douma KF; van Tinteren H; Peterse JL; Wesseling J; Wu TS; Atsma D; Rutgers EJ; Brink G; Floore AN; Glas AM; Roumen RM; Bellot FE; van Krimpen C; Rodenhuis S; van de Vijver MJ; Linn SC
Lancet Oncol; 2007 Dec; 8(12):1079-1087. PubMed ID: 18042430
[TBL] [Abstract][Full Text] [Related]
36. Long-term follow-up of axillary recurrences after negative sentinel lymph node biopsy: effect on prognosis and survival.
Bulte JP; van Wely BJ; Kasper S; Kuijt G; van den Wildenberg FJ; Strobbe LJ; de Wilt JH
Breast Cancer Res Treat; 2013 Jul; 140(1):143-9. PubMed ID: 23793602
[TBL] [Abstract][Full Text] [Related]
37. Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.
Martin M; Brase JC; Calvo L; Krappmann K; Ruiz-Borrego M; Fisch K; Ruiz A; Weber KE; Munarriz B; Petry C; Rodriguez CA; Kronenwett R; Crespo C; Alba E; Carrasco E; Casas M; Caballero R; Rodriguez-Lescure A
Breast Cancer Res; 2014 Apr; 16(2):R38. PubMed ID: 24725534
[TBL] [Abstract][Full Text] [Related]
38. Mortality rates among early-stage hormone receptor-positive breast cancer patients: a population-based cohort study in Denmark.
Christiansen P; Bjerre K; Ejlertsen B; Jensen MB; Rasmussen BB; Lænkholm AV; Kroman N; Ewertz M; Offersen B; Toftdahl DB; Møller S; Mouridsen HT;
J Natl Cancer Inst; 2011 Sep; 103(18):1363-72. PubMed ID: 21881042
[TBL] [Abstract][Full Text] [Related]
39. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
Partin JF; Mamounas EP
Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
